Ramsay Generale de Sante (GDS) AI Stock Analysis

• Market Cap: €1.21B
• Dividend Yield: N/A
• Average Volume (3M): 572.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.07
• Revenue Growth: 5.79%
• EPS Growth: -575.58%
• Country: FR
• Employees: 34,218
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Care Facilities
• EPS (TTM): -0.72
• Shares Outstanding: 110,389,690
• 10 Day Avg. Volume: 318
• 30 Day Avg. Volume: 572
• PEG Ratio: -0.79
• Price to Book (P/B): 1.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 5.28
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: €11.50 ▲(4.07%Upside)

The overall stock score reflects a mixed financial performance, with strengths in cash flow but significant profitability challenges and high leverage. Technical indicators suggest positive momentum, while valuation is constrained by a negative P/E ratio and lack of dividend yield.

Ramsay Generale de Sante Business Overview & Revenue Model

Company Description

Ramsay Générale de Santé (GDS) is a leading private healthcare provider in France, operating a network of hospitals and clinics. The company offers a comprehensive range of medical services, including acute care, surgery, maternity care, oncology treatment, and rehabilitation. With a focus on delivering high-quality healthcare services, Ramsay Générale de Santé aims to meet the needs of patients across various medical specializations through its extensive network of healthcare facilities.

How the Company Makes Money

Ramsay Générale de Santé generates revenue primarily through patient services provided at its network of hospitals and clinics. The company earns money by billing for medical procedures, inpatient and outpatient care, and additional healthcare services such as diagnostic tests and consultations. Revenue streams are driven by reimbursements from public and private health insurance systems, as well as direct payments from patients. Additionally, strategic partnerships with healthcare professionals and collaborations with insurance providers and public health entities enhance its service offerings and contribute to its earnings.

Ramsay Generale de Sante Financial Statement Overview

Summary

Ramsay Generale de Sante shows a mixed financial picture. While revenue growth is positive, profitability has been impacted, leading to a negative net income. The balance sheet highlights high leverage, which could pose risks in managing liabilities. Cash flow generation remains a strength, providing some stability despite profit challenges. The company needs to address profitability issues to improve its overall financial health.

Income Statement

The income statement shows mixed performance. Revenue has grown steadily from $4.02B in 2021 to $5.14B TTM, with a recent growth rate of 2.74% compared to the previous annual period. However, net income has turned negative in the TTM period, indicating profitability challenges. EBIT and EBITDA margins have declined, reflecting operational inefficiencies or increased costs.

Balance Sheet

The balance sheet reveals high leverage with a debt-to-equity ratio of 3.48 in the TTM period, indicating significant reliance on borrowed funds. Stockholders' equity has decreased, and the equity ratio stands at 17.37%, suggesting limited equity buffer against liabilities. The return on equity has turned negative due to the net loss, highlighting concerns about current profitability.

Cash Flow

Cash flow analysis shows some strengths, with positive free cash flow of $440M in TTM and a 5.19% growth from the previous period. The operating cash flow to net income ratio is robust due to strong cash flow generation despite a net loss. However, the free cash flow to net income ratio highlights the pressure on profitability.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	5.14B	5.01B	4.70B	4.30B	4.02B	3.75B
Gross Profit	1.41B	3.94B	3.72B	3.41B	3.20B	3.01B
EBITDA	535.50M	591.30M	656.30M	691.00M	604.00M	543.80M
Net Income	-79.70M	-53.90M	49.40M	118.40M	65.00M	18.70M
Balance Sheet
Total Assets	6.49B	6.90B	6.96B	6.79B	6.68B	6.71B
Cash, Cash Equivalents and Short-Term Investments	157.80M	381.30M	362.90M	143.50M	620.00M	548.20M
Total Debt	3.92B	4.06B	4.15B	3.97B	3.85B	3.92B
Total Liabilities	5.33B	5.67B	5.68B	5.55B	5.58B	5.68B
Stockholders Equity	1.13B	1.19B	1.25B	1.21B	1.07B	1.01B
Cash Flow
Free Cash Flow	440.00M	418.30M	426.70M	68.90M	475.90M	560.90M
Operating Cash Flow	607.50M	586.80M	598.90M	262.50M	652.30M	729.60M
Investing Cash Flow	-164.20M	-180.50M	-175.40M	-471.10M	-181.40M	-186.20M
Financing Cash Flow	-470.30M	-401.50M	-197.10M	-264.20M	-390.60M	-377.20M

Ramsay Generale de Sante Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GDS, the sentiment is Positive. The current price of 11.05 is above the 20-day moving average (MA) of 11.04, above the 50-day MA of 10.52, and below the 200-day MA of 11.16, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 58.45 is Neutral, neither overbought nor oversold. The STOCH value of 45.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:GDS.

Ramsay Generale de Sante Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIRP	76 Outperform	€2.78B	19.13	14.95%	0.44%	12.07%	20.48%
VETO	76 Outperform	€884.60M	15.03	10.64%	1.19%	1.88%	5.79%
LNA	74 Outperform	€271.97M	12.23	7.12%	29.89%	9.58%	-6.69%
CLARI	66 Neutral	€1.86B	―	-0.83%	―	4.64%	57.96%
GDS	61 Neutral	€1.21B	―	-6.74%	―	5.79%	-575.58%
Sector *	55 Neutral	€4.60B	16.80	-50.16%	3.64%	15.33%	-9.51%
EMEIS	47 Neutral	€1.84B	0.02	-22.82%	―	8.43%	-102.06%